| NCT06126380 | Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients | ENROLLING_BY_INVITATION | PHASE2 | 2023-10-25 | 2029-12 | 2029-12 |
| NCT05983770 | Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-08-30 | 2025-03 | 2025-03 |
| NCT05480657 | Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D | WITHDRAWN | PHASE1, PHASE2 | 2022-09-30 | 2028-08 | 2024-08 |
| NCT05125068 | Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN) | TERMINATED | PHASE2 | 2022-03-21 | 2023-07-31 | 2023-07-31 |
| NCT05027906 | Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant | RECRUITING | PHASE1, PHASE2 | 2022-02-18 | 2027-01 | 2027-01 |
| NCT04711226 | Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation | WITHDRAWN | PHASE2 | 2021-02-19 | 2026-06 | 2024-06 |
| NCT04322149 | Multiple Doses of AT-1501-A201 in Adults With ALS | COMPLETED | PHASE2 | 2020-10-16 | 2022-03-24 | 2022-03-24 |